Making a difference, patient by patient
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs
Patients are key to everything that we do at US WorldMeds
We will remain a sustainable, privately held specialty pharmaceutical company.
We will develop, license, and market meaningful and accessible healthcare products that improve lives and result in a thriving community of patients, employees, and shareholders.
We will embrace a culture that values honesty, creativity, and action, integrity in relationships, a passion for success, and good stewardship of Company resources. We will endeavor to develop, recognize, reward, and retain teammates who deliver results and embody our Vision and Mission.
Our people bring US WorldMeds to life
The leadership team at US WorldMeds
Founder and Member of the Board of Directors
Over 25 years of experience in Pharmaceutical Operations, Sales Management, Marketing and National Accounts
Professor Emeritus of Medicinal Chemistry at University of Kentucky College of Pharmacy
25 years of experience in Medical Affairs and Marketing
20 years of experience in Operational Accounting, Finance and Development
Over 10 years of experience in Pharmaceutical Development Strategy, Clinical Operations and Regulatory Affairs
QUICK ACCESS TO THE LATEST COMPANY NEWS
Discover the latest news, featured stories, and past news from US WorldMeds
March 31, 2022 |
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths
LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and availability of ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.
-News Archives (Click)-
July 09, 2020 |
US WorldMeds Announces Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic
Company will donate opioid withdrawal medication LUCEMYRA® (lofexidine) to patients in need
LOUISVILLE, Ky., July 9, 2020 (PRNewswire) -- USWM LLC dba US WorldMeds (USWM), a Kentucky-based company, has today announced their partnership with the Federal Emergency Management (FEMA) and Healthcare Ready in bringing urgently needed opioid withdrawal medication to communities in need during the current coronavirus pandemic.
August 06, 2018 |
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets
First and only FDA-approved, non-opioid medication indicated for mitigation of opioid withdrawal symptoms is now available for prescription
LOUISVILLE, Ky. and BRIDGEWATER, N.J., Aug. 6, 2018 (PRNewswire) -- US WorldMeds, LLC, and Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Inc. (NYSE/TSX: BHC), today announced the U.S. launch and availability of LUCEMYRA™ (lofexidine) 0.18 mg tablets, the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to abrupt opioid discontinuation in adults.